-
Over 18 billion yuan of market, a large number of domestic pharmaceutical companies are actively layout!
Time of Update: 2022-10-12
Recently, there have been reports that the FDA has approved Auvelity, a new drug developed by Axsome, for the treatment of Major Depressive Disorder (MDD) in adults.
-
Notice on the Public Solicitation of Opinions on the Guiding Principles for the Identification, Management and Evaluation of Drug-induced Liver Injury in Clinical Trials
Time of Update: 2022-10-12
docx for Solicitation of Comments Notice on the Public Solicitation of Opinions on the Guiding Principles for the Identification, Management and Evaluation of Drug-induced Liver Injury in Clinical Trials Release date: 20221008 To further guide the assessment of the potential for drug-induced liver injury in clinical trials of drugs, to ensure the safety of subjects, and to obtain safety information to assess the risk characteristics of the drug in the trial.
-
The cooperation between Chinese and foreign pharmaceutical companies has become more frequent, and the content of cooperation has shown a trend of diversification
Time of Update: 2022-10-12
【Pharmaceutical Network Industry News】The cooperation between Chinese and foreign pharmaceutical companies is becoming more and more frequent, and the cooperation content is diversified Recently, the signing ceremony of Merck Group's trademark license and the signing of the biological wisdom valley (Chengdu) Technology Co.
-
Notice on the "Symposium on the Selection and Safety Evaluation of Excipients for Children's Drugs"
Time of Update: 2022-10-12
Notice on the "Symposium on the Selection and Safety Evaluation of Excipients for Children's Drugs" Release date: 20220930 In order to encourage the research and development of children's drugs and e
-
Aiming at the CDMO business, multinational pharmaceutical companies have "marriages" and sell-offs
Time of Update: 2022-10-12
【Pharmaceutical Network Industry News】On October 10, the news was officially held at the signing ceremony of the trademark license of Merck Group of multinational pharmaceutical company Merck Group Tr
-
In order to enhance competitiveness, pharmaceutical companies are vigorously building R&D production bases
Time of Update: 2022-10-12
【Pharmaceutical Network Industry News】Recently, the "New Leading (Chongqing) Biomedical Integration R&D Service Base" project invested and built by Beijing New Leading Pharmaceutical Science and Technology Development Co.
-
The reform of traditional Chinese medicine medical insurance payment methods has accelerated, and many places have ushered in new breakthroughs
Time of Update: 2022-10-12
In 2021, the Medical Security Bureau of the Autonomous Region launched the pilot project of "Payment Methods Suitable for the Characteristics of Traditional Chinese Medicine under the Comprehensive Reform of Medical Insurance DRG Payment" in Liuzhou, and the reform path mainly includes payment for the dominant diseases of traditional Chinese medicine, payment according to the value of curative effect, and payment according to the diagnosis of Western medicine in the dual diagnosis into the DRG group.
-
Letter on the Public Solicitation of Opinions on the Guiding Principles for the Naming of Generic Names of Chemical Drugs
Time of Update: 2022-10-12
xlsx In order to do a good job in the naming of generic names of chemical drugs, our committee has organized the drafting of the "Guiding Principles for the Naming of Common Names of Chemical Drugs (Draft for Solicitation of Comments)" (see Annex 1), which is now open to the public for comments.
-
Novartis Pharmaceuticals: To be the top five pharmaceutical companies in the United States and the top three in China
Time of Update: 2022-10-12
Establish the China Center for Evidence-Based Medicine of Traditional Chinese Medicine, build a multi-dimensional evaluation technology system for proprietary Chinese medicines, carry out evidence-based evaluation of dominant diseases in traditional Chinese medicine, and provide guidance for the rational use of drugs in clinical practice.
-
Technical Guidelines for the Study of Quality Properties of Chewable Tablets (Chemicals) (Draft for Solicitation of Comments) Released
Time of Update: 2022-10-12
Transferred from: CDE Editor: On September 26, CDE publicly solicited opinions on the "Technical Guidelines for the Study of Quality Properties of Chewable Tablets (Chemicals) (Draft for Comments)" 。
-
Starting next month, the major pharmaceutical provinces will include a large number of traditional Chinese medicine formula granules in medical insurance
Time of Update: 2022-10-12
【Pharmaceutical Network Industry News】Chinese medicine formula granules are an important part of traditional Chinese medicine, which is a "modern" product of traditional Chinese medicine, with the adv
-
Together for a long time! The road to the spin-off of multinational giants in 2022
Time of Update: 2022-10-12
In August, Novartis announced plans to 100% divest its generic and biosimilar division, Sandoz, into a newly listed independent operating company, with the spin-off process expected to be completed in the second half of next year.
-
The third quarterly report of the listed company is about to be disclosed, and the pharmaceutical company is expected to get the first attention
Time of Update: 2022-10-12
On September 19, Kaipu Bio released the first three quarters of 2022 performance forecast, during the reporting period, the net profit attributable to the shareholders of the listed company is expected to be 1.
-
The new Pharmacopoeia Committee was established, and the preparation of the 2025 edition of the Chinese Pharmacopoeia was launched!
Time of Update: 2022-10-12
It is necessary to continuously improve the scientificity, advancedness, practicality and standardization of pharmacopoeia, and strengthen the guiding role of the Chinese Pharmacopoeia in ensuring the safety, effectiveness and quality control of drugs; Implement the concept of drug life cycle management, actively explore the development strategy of drug standards, give full play to the important technical support role of drug standards for drug supervision, and promote the improvement of regulatory capabilities.
-
The merger and acquisition of Kailai Ying and Zhongsheng Pharmaceutical have encountered obstacles one after another! Under the US New Deal, the internationalization of Chinese pharmaceutical companies needs real innovation!
Time of Update: 2022-10-12
On the evening of June 23, Zhongsheng Pharmaceutical announced that it had reached a merger agreement and plans to acquire all outstanding common shares of F-star, a NASDAQ-listed company, for a total consideration of $161 million, or $7.
-
Notice on the Public Solicitation of Opinions on the Technical Guidelines for the Pharmacological Research of New Medicinal Compounds of Traditional Chinese Medicines Based on Human Experience (Draft for Solicitation of Comments).
Time of Update: 2022-10-12
Drug Evaluation Center of the State Drug Administration September 27, 2022 Related Attachments serial number The attachment name 1 Technical Guidelines for the Pharmacological Research of New Pharmacognostics of Traditional Chinese Medicine Compound Preparations Based on Human Experience (Draft for Solicitation of Comments).
-
Keji Pharmaceutical Announces 2022 Interim Results: Continue to Promote CAR-T Technology Innovation and Product Pipeline
Time of Update: 2022-10-06
SHANGHAI, Aug. 24, 2022 /PRNewswire/ -- Keji Pharmaceuticals, an innovative CAR-T cell therapy company primarily focused on the treatment of hematological malignancies and solid tumors, has announced
-
The CCR8-targeting monoclonal antibody CM369 jointly developed by Nuocheng Jianhua and Connoya has been approved for clinical use
Time of Update: 2022-10-06
BEIJING, Aug. 24, 2022 /PRNewswire/ -- Nuocheng Jianhua and Connoya jointly announced today that they have received the "Notice of Drug Clinical Trial Approval" approved and issued by the State Drug Administration The CCR8-targeting monoclonal antibody CM369 developed by Nuojiancheng has carried out clinical trials in advanced solid tumors .
-
Guiding opinions on further promoting the development of the integration of medical and nursing care
Time of Update: 2022-10-06
All relevant departments in all localities should adhere to the guidance of Xi Jinping Thought on Socialism with Chinese Characteristics for a New Era, conscientiously implement the decision-making and deployment of the Party Central Committee and the State Council, further improve policies and measures, focus on solving difficult problems and blockages, promote the development of medical and nursing care, and continuously meet the needs of health and old-age services for the elderly.
-
Junshi Biologics' JS110 (XPO1 inhibitor) clinical trial application was approved by the US FDA
Time of Update: 2022-10-03
Shanghai, August 25, 2022 /PRNewswire/ -- On August 25, 2022, Beijing time, Junshi Biologics announced that the clinical trial application of the XPO1 inhibitor WJ01024 tablets (project code: JS110) jointly developed by the company and Micro Bio has been approved by the US Food and Drug Administration (FDA).
